van der Voorn SM, van Drie E, Proost V, et al. Lack of Evidence for the Role of the p.(Ser96Ala) Polymorphism in Histidine-Rich Calcium Binding Protein as a Secondary Hit in Cardiomyopathies. International journal of molecular sciences. 2023;24(21). doi:10.3390/ijms242115931.

Whiffin N, Minikel E, Walsh R, et al. Using high-resolution variant frequencies to empower clinical genome interpretation. Genet Med. 2017;19(10):1151-1158. doi:10.1038/gim.2017.26.

Feichtinger RG, Oláhová M, Kishita Y, et al. Biallelic C1QBP Mutations Cause Severe Neonatal-, Childhood-, or Later-Onset Cardiomyopathy Associated with Combined Respiratory-Chain Deficiencies. Am J Hum Genet. 2017;101(4):525-538. doi:10.1016/j.ajhg.2017.08.015.

Newton-Cheh C. Should Identifying a Titin Truncating Variant Change the Management of Patients With Dilated Cardiomyopathy?. J Am Coll Cardiol. 2017;70(18):2275-2277. doi:10.1016/j.jacc.2017.09.020.

Landry LG, Rehm HL. Association of Racial/Ethnic Categories With the Ability of Genetic Tests to Detect a Cause of Cardiomyopathy. JAMA Cardiol. 2018;3(4):341-345. doi:10.1001/jamacardio.2017.5333.

Liu Y, Asnani A, Zou L, et al. Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase. Sci Transl Med. 2014;6(266):266ra170. doi:10.1126/scitranslmed.3010189.